Equities

Shield Therapeutics PLC

STX:LSE

Shield Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)4.80
  • Today's Change0.05 / 1.05%
  • Shares traded3.05m
  • 1 Year change-50.77%
  • Beta1.5809
Data delayed at least 20 minutes, as of Sep 27 2024 16:01 BST.
More ▼

Profile data is unavailable for this security.

About the company

Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anaemia. The Company operates through two segments: Feraccru (ferric maltol), and PT20. Its lead product Accrufer/Feraccru is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, United Kingdom, and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.

  • Revenue in GBP (TTM)20.88m
  • Net income in GBP-36.17m
  • Incorporated2015
  • Employees73.00
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Genflow Biosciences PLC0.00-1.63m7.44m5.007.44m5.00
Synairgen plc0.00-6.92m7.67m36.007.67m36.00
Cizzle Biotechnology Holdings PLC0.00-1.72m7.75m67.007.75m67.00
LungLife AI Inc21.69k-3.34m8.50m15.008.50m15.00
Oxford Biodynamics PLC617.00k-11.11m11.91m45.0011.91m45.00
OptiBiotix Health PLC644.00k-2.04m16.53m5.0016.53m5.00
Hemogenyx Pharmaceuticals PLC0.00-6.69m20.67m17.0020.67m17.00
Skinbiotherapeutics PLC161.65k-2.88m26.26m11.0026.26m11.00
Arecor Therapeutics PLC4.57m-8.55m29.55m50.0029.55m50.00
Sareum Holdings Plc0.00-4.26m29.56m5.0029.56m5.00
Incanthera PLC0.00-1.55m29.73m7.0029.73m7.00
Shield Therapeutics PLC20.88m-36.17m32.89m73.0032.89m73.00
Poolbeg Pharma PLC0.00-4.38m52.33m8.0052.33m8.00
Data as of Sep 27 2024. Currency figures normalised to Shield Therapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

26.86%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Asset Management Ltd.as of 23 Apr 202464.05m8.19%
Jupiter Asset Management Ltd.as of 21 Jul 202334.13m4.36%
Premier Fund Managers Ltd.as of 05 May 202330.00m3.84%
LGT Capital Partners AG (Investment Management)as of 01 Aug 202428.70m3.67%
IG Markets Ltd.as of 01 Aug 202412.82m1.64%
Killik & Co. LLPas of 05 May 202310.62m1.36%
Jarvis Investment Management Ltd.as of 01 Aug 20249.61m1.23%
KW Investment Management Ltd.as of 01 Aug 20249.35m1.20%
Rahn+Bodmer Co.as of 01 Aug 20245.72m0.73%
USS Investment Management Ltd.as of 19 Mar 20215.07m0.65%
More ▼
Data from 30 Jun 2024 - 06 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.